These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26608306)

  • 1. Long-term medical treatment in congenital hyperinsulinism: a descriptive analysis in a large cohort of patients from different clinical centers.
    Welters A; Lerch C; Kummer S; Marquard J; Salgin B; Mayatepek E; Meissner T
    Orphanet J Rare Dis; 2015 Nov; 10():150. PubMed ID: 26608306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Long-Acting Somatostatin Analogue (Lanreotide) in an Adolescent with Diazoxide-Responsive Congenital Hyperinsulinism and Its Psychological Impact.
    Shah P; Rahman SA; McElroy S; Gilbert C; Morgan K; Hinchey L; Senniappan S; Levy H; Amin R; Hussain K
    Horm Res Paediatr; 2015; 84(5):355-60. PubMed ID: 26375451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term lanreotide treatment in six patients with congenital hyperinsulinism.
    Kühnen P; Marquard J; Ernert A; Meissner T; Raile K; Wannenmacher G; Blankenstein O
    Horm Res Paediatr; 2012; 78(2):106-12. PubMed ID: 22907123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism.
    Corda H; Kummer S; Welters A; Teig N; Klee D; Mayatepek E; Meissner T
    Orphanet J Rare Dis; 2017 Jun; 12(1):108. PubMed ID: 28576129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment effect of diazoxide on 44 patients with congenital hyperinsulinism.
    Hu S; Xu Z; Yan J; Liu M; Sun B; Li W; Sang Y
    J Pediatr Endocrinol Metab; 2012; 25(11-12):1119-22. PubMed ID: 23329758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry.
    Hosokawa Y; Kawakita R; Yokoya S; Ogata T; Ozono K; Arisaka O; Hasegawa Y; Kusuda S; Masue M; Nishibori H; Sairenchi T; Yorifuji T
    Endocr J; 2017 Sep; 64(9):867-880. PubMed ID: 28701683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism.
    van der Steen I; van Albada ME; Mohnike K; Christesen HT; Empting S; Salomon-Estebanez M; Greve Rasmussen A; Verrijn Stuart A; van der Linde AAA; Banerjee I; Boot AM
    Horm Res Paediatr; 2018; 89(2):82-89. PubMed ID: 29241206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conservatively treated Congenital Hyperinsulinism (CHI) due to K-ATP channel gene mutations: reducing severity over time.
    Salomon-Estebanez M; Flanagan SE; Ellard S; Rigby L; Bowden L; Mohamed Z; Nicholson J; Skae M; Hall C; Craigie R; Padidela R; Murphy N; Randell T; Cosgrove KE; Dunne MJ; Banerjee I
    Orphanet J Rare Dis; 2016 Dec; 11(1):163. PubMed ID: 27908292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The use of long-acting somatostatin analogs in congenital hyperinsulinism].
    Novokreshhennyx EE; Gubaeva DN; Melikyan MA
    Probl Endokrinol (Mosk); 2020 Oct; 66(5):70-78. PubMed ID: 33369374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of diabetes following pancreatic surgery in patients with congenital hyperinsulinism.
    Welters A; Meissner T; Grulich-Henn J; Fröhlich-Reiterer E; Warncke K; Mohnike K; Blankenstein O; Menzel U; Datz N; Bollow E; Holl RW
    Orphanet J Rare Dis; 2018 Dec; 13(1):230. PubMed ID: 30577875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of children with congenital hyperinsulinism on octreotide therapy.
    Demirbilek H; Shah P; Arya VB; Hinchey L; Flanagan SE; Ellard S; Hussain K
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3660-7. PubMed ID: 24937539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal congenital hyperinsulinism managed by medical treatment: a diagnostic algorithm based on molecular genetic screening.
    Maiorana A; Barbetti F; Boiani A; Rufini V; Pizzoferro M; Francalanci P; Faletra F; Nichols CG; Grimaldi C; de Ville de Goyet J; Rahier J; Henquin JC; Dionisi-Vici C
    Clin Endocrinol (Oxf); 2014 Nov; 81(5):679-88. PubMed ID: 24383515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.
    Herrera A; Vajravelu ME; Givler S; Mitteer L; Avitabile CM; Lord K; De León DD
    J Clin Endocrinol Metab; 2018 Dec; 103(12):4365-4372. PubMed ID: 30247666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nifedipine in Congenital Hyperinsulinism - A Case Report.
    Khawash P; Hussain K; Flanagan SE; Chatterjee S; Basak D
    J Clin Res Pediatr Endocrinol; 2015 Jun; 7(2):151-4. PubMed ID: 26316440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The difficult management of persistent, non-focal congenital hyperinsulinism: A retrospective review from a single, tertiary center.
    Rasmussen AG; Melikian M; Globa E; Detlefsen S; Rasmussen L; Petersen H; Brusgaard K; Rasmussen AH; Mortensen MB; Christesen HT
    Pediatr Diabetes; 2020 May; 21(3):441-455. PubMed ID: 31997554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Congenital hyperinsulinism: management and outcome, a single tertiary centre experience.
    El Tonbary K; Robinson P; Banerjee I; Shaikh MG
    Eur J Pediatr; 2020 Jun; 179(6):947-952. PubMed ID: 32002613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Continuous subcutaneous infusion of somatostatin analogues in the treatment of congenital hyperinsulinism].
    Melikyan MA; Gubaeva DN; Kareva MA
    Probl Endokrinol (Mosk); 2020 Sep; 66(3):81-87. PubMed ID: 33351342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Dose-Titrated Glucagon Infusions in the Management of Congenital Hyperinsulinism: A Case Series.
    Salomon-Estebanez M; Yau D; Dunne MJ; Worth C; Birch S; Walewski JL; Banerjee I
    Front Endocrinol (Lausanne); 2020; 11():441. PubMed ID: 33013678
    [No Abstract]   [Full Text] [Related]  

  • 19. Octreotide-related exocrine pancreatic insufficiency (EPI) in congenital hyperinsulinism.
    Ros-Pérez P; Golmayo L; Cilleruelo ML; Gutiérrez C; Celaya P; Lacámara N; Martínez-Badás I; Güemes M; Argente J
    J Pediatr Endocrinol Metab; 2020 Jul; 33(7):947-950. PubMed ID: 32634108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rare forms of congenital hyperinsulinism.
    Marquard J; Palladino AA; Stanley CA; Mayatepek E; Meissner T
    Semin Pediatr Surg; 2011 Feb; 20(1):38-44. PubMed ID: 21186003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.